Browse CRYM

Summary
SymbolCRYM
Namecrystallin, mu
Aliases thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location16p12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain PF02423 Ornithine cyclodeaminase/mu-crystallin family
Function

Specifically catalyzes the reduction of imine bonds in brain substrates that may include cystathionine ketimine (CysK) and lanthionine ketimine (LK). Binds thyroid hormone which is a strong reversible inhibitor. Presumably involved in the regulation of the free intracellular concentration of triiodothyronine and access to its nuclear receptors.

> Gene Ontology
 
Biological Process GO:0006520 cellular amino acid metabolic process
GO:0006553 lysine metabolic process
GO:0006554 lysine catabolic process
GO:0006575 cellular modified amino acid metabolic process
GO:0007605 sensory perception of sound
GO:0009063 cellular amino acid catabolic process
GO:0009066 aspartate family amino acid metabolic process
GO:0009068 aspartate family amino acid catabolic process
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0016054 organic acid catabolic process
GO:0018958 phenol-containing compound metabolic process
GO:0042403 thyroid hormone metabolic process
GO:0042445 hormone metabolic process
GO:0044282 small molecule catabolic process
GO:0046395 carboxylic acid catabolic process
GO:0050954 sensory perception of mechanical stimulus
GO:0070327 thyroid hormone transport
GO:0072337 modified amino acid transport
GO:1901565 organonitrogen compound catabolic process
GO:1901605 alpha-amino acid metabolic process
GO:1901606 alpha-amino acid catabolic process
GO:1901615 organic hydroxy compound metabolic process
Molecular Function GO:0003714 transcription corepressor activity
GO:0016645 oxidoreductase activity, acting on the CH-NH group of donors
GO:0016646 oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor
GO:0042562 hormone binding
GO:0047127 thiomorpholine-carboxylate dehydrogenase activity
GO:0048037 cofactor binding
GO:0050661 NADP binding
GO:0050662 coenzyme binding
GO:0070324 thyroid hormone binding
Cellular Component GO:0005777 peroxisome
GO:0005782 peroxisomal matrix
GO:0031907 microbody lumen
GO:0042579 microbody
GO:0044438 microbody part
GO:0044439 peroxisomal part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-6788656: Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism
R-HSA-71064: Lysine catabolism
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
Summary
SymbolCRYM
Namecrystallin, mu
Aliases thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location16p12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CRYM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCRYM
Namecrystallin, mu
Aliases thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location16p12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CRYM in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCRYM
Namecrystallin, mu
Aliases thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location16p12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CRYM in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2620.526
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1160.872
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5340.361
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.070.0498
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.3490.244
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7070.567
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.840.18
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1790.847
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-2.110.025
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.90.549
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.7010.408
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3160.283
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CRYM in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916018.8-18.80.28
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCRYM
Namecrystallin, mu
Aliases thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location16p12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CRYM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCRYM
Namecrystallin, mu
Aliases thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location16p12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CRYM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CRYM.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCRYM
Namecrystallin, mu
Aliases thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location16p12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CRYM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCRYM
Namecrystallin, mu
Aliases thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location16p12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CRYM expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCRYM
Namecrystallin, mu
Aliases thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location16p12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CRYM and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCRYM
Namecrystallin, mu
Aliases thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location16p12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CRYM collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CRYM.
ID Name Drug Type Targets #Targets
DB05235NRP409Small MoleculeCRYM, THRA2